PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medigene Immunotherapies GMBH

USPTO PatentsView assignee record - 12 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medigene ranks #22,962 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 6 technology areas.

#22,962
of 49,997 US assignees by volume
Top 40%
by Innovation Score (38.5/100)
16.5
avg claims per patent

USPTO PatentsView assignee plate

Corpus R22962 · Foreign Corporation #22,962 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 12 grants
  • MID-PACK #22,962/49,997
  • PHOTO-FINISH Materion Newton
  • CPC-NARROW C07K · 6 areas
  • INNOV-THIN 38.5/100
  • CLAIMS-RICH 16.5 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Materion Newton Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medigene’s 38.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Medigene

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Medigene's Innovation Score is 38.5/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Medigene?

Each dot is one of Medigene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medigene’s own 16.5 claims/patent is at or below the 18.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Medigene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 11.911.91212.1 5101520253035 Granted patents (volume) Avg claims / patent Materion Newton Inc. - 12, 21.17Materion NewtonMaxlinear Asia Singapore Private Limited - 12, 27Maxlinear Asia Si…Media IP, Inc. - 12, 23.75Media IPMedical Microinstruments, Inc. - 12, 18.5Medical Microinst…Medipost Co., Ltd - 12, 7.25MedipostMeiji University - 12, 14.25Meiji UniversityMeissner Filtration Products, Inc. - 12, 29.17Meissner Filtrati…Melitta Single Portions GMBH & Co. KG - 12, 12.33Melitta Single Po…Medigene Immunotherapies GMBH - 12, 16.5Medigene Immunoth…
Medigene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medigene's grants concentrate

Medigene Immunotherapies GMBH is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2020. By volume, Medigene sits between Materion Newton Inc. and Melitta Single Portions GMBH & Co. KG.

Medigene's three-year grant acceleration

Medigene Immunotherapies GMBH shows 5 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Medigene's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Medigene holds 12 patents at rank #22,935, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Medigene

By rank, the assignees closest to #22,935 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Medigene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Medigene, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Medigene ranks #755 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Nocira, LLC 39 Nidec-shimpo Corporation 39 Quick Fitting Holding Company, LLC 39 Phoenix Contact E-mobility GMBH 39

Medigene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 202020212022202320242025 4
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Medigene Immunotherapies GMBH patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 8.3%
2021 2 16.7%
2022 2 16.7%
2023 1 8.3%
2024 2 16.7%
2025partial year 4 33.3%

Which technologies does Medigene Immunotherapies GMBH patent most?

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medigene Immunotherapies GMBH's patent record in context - here's where to go next.

  • Medigene Immunotherapies GMBH's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #22,962 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Medigene Immunotherapies GMBH against Materion Newton Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 38.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.